328 related articles for article (PubMed ID: 24677117)
1. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
[TBL] [Abstract][Full Text] [Related]
2. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
4. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
Funck-Brentano C; Szymezak J; Steichen O; Ducint D; Molimard M; Remones V; Azizi M; Gaussem P
Arch Cardiovasc Dis; 2013 Dec; 106(12):661-71. PubMed ID: 24246616
[TBL] [Abstract][Full Text] [Related]
5. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
[TBL] [Abstract][Full Text] [Related]
6. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
[TBL] [Abstract][Full Text] [Related]
7. Influence of low-dose proton pump inhibitors administered concomitantly or separately on the anti-platelet function of clopidogrel.
Furuta T; Sugimoto M; Kodaira C; Nishino M; Yamade M; Uotani T; Sahara S; Ichikawa H; Kagami T; Iwaizumi M; Hamaya Y; Osawa S; Sugimoto K; Umemura K
J Thromb Thrombolysis; 2017 Apr; 43(3):333-342. PubMed ID: 27981489
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
9. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.
Sibbing D; Morath T; Stegherr J; Braun S; Vogt W; Hadamitzky M; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2009 Apr; 101(4):714-9. PubMed ID: 19350116
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers.
Andersson T; Morrison D; Nagy P; Pisupati J; Schettler J; Warner TD
Am J Cardiovasc Drugs; 2012 Aug; 12(4):217-24. PubMed ID: 22631032
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and safety of a fixed-dose combination of acetylsalicylic acid and clopidogrel compared with the concurrent administration of acetylsalicylic acid and clopidogrel in healthy subjects: a randomized, open-label, 2-sequence, 2-period, single-dose crossover study.
Jung JA; Kim TE; Kim JR; Kim MJ; Huh W; Park KM; Lee SY; Ko JW
Clin Ther; 2013 Jul; 35(7):985-94. PubMed ID: 23870608
[TBL] [Abstract][Full Text] [Related]
13. The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
J Cardiovasc Pharmacol; 2010 Nov; 56(5):532-9. PubMed ID: 20729752
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Chen CH; Yang JC; Uang YS; Lin CJ
Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.
Przespolewski ER; Westphal ES; Rainka M; Smith NM; Bates V; Gengo FM
J Stroke Cerebrovasc Dis; 2018 Jun; 27(6):1582-1589. PubMed ID: 29449127
[TBL] [Abstract][Full Text] [Related]
16. Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.
Neubauer H; Engelhardt A; Krüger JC; Lask S; Börgel J; Mügge A; Endres HG
J Cardiovasc Pharmacol; 2010 Jul; 56(1):91-7. PubMed ID: 20410834
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
Fernando H; Bassler N; Habersberger J; Sheffield LJ; Sharma R; Dart AM; Peter KH; Shaw JA
J Thromb Haemost; 2011 Aug; 9(8):1582-9. PubMed ID: 21696537
[TBL] [Abstract][Full Text] [Related]
18. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
19. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.
Gilard M; Arnaud B; Cornily JC; Le Gal G; Lacut K; Le Calvez G; Mansourati J; Mottier D; Abgrall JF; Boschat J
J Am Coll Cardiol; 2008 Jan; 51(3):256-60. PubMed ID: 18206732
[TBL] [Abstract][Full Text] [Related]
20. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
Johnson DA; Chilton R; Liker HR
Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]